Side-by-side comparison of AI visibility scores, market position, and capabilities
Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Series B in 2023 led by Novo Holdings and Foresite Capital; headquartered in San Francisco;
Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is developing a new class of therapeutics — cell-permeable macrocycles — designed to inhibit intracellular protein-protein interactions (PPIs) that have historically been considered "undruggable." Protein-protein interactions control critical cellular processes including cell division, apoptosis (programmed cell death), and gene expression. Dysregulation of these interactions drives many cancers, but their large, flat interaction surfaces are difficult to block with small molecules, and biologics (antibodies) cannot cross cell membranes to reach intracellular targets. Circle Pharma's macrocycles are medium-sized ring-shaped molecules engineered to be both cell-permeable and orally bioavailable — a combination rarely achieved — enabling them to reach and inhibit these targets.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.